...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Surgical Endoscopy >Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study
【24h】

Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study

机译：肝细胞癌肝细胞癌的安全性和可行性，具有临床显着的门肠性高血压：倾向分数匹配研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The presence of clinically significant portal hypertension (CSPH) remains a relative contraindication to liver resection for patients with resectable hepatocellular carcinoma (HCC). The goal of this study was to explore whether a laparoscopic approach could extend the indications for hepatectomy to patients with PH. Method Patients who underwent laparoscopic liver resection (LLR) from February 2016 to September 2019 performed by a single medical team were included in this study. We analyzed the surgical and oncological outcomes between groups with and without CSPH before and after propensity score matching (PSM). Result We enrolled 156 patients divided into two groups according to the presence (CSPH,n = 26) or absence (non-CSPH,n = 130) of CSPH. CSPH group was associated with more clinical signs of liver dysfunction (p < 0.05). After PSM (n = 48 patients), the CSPH group tended to have a longer postoperative hospital stay (p = 0.054); however, there was no difference in operation time (p = 0.329), blood loss volume (p = 0.392), transfusion rates (p = 0.701), rate of conversion to open surgery (p = 0.666), surgical margin (p = 0.306), surgical mortality (n = 0), or comprehensive complication index (p = 0.844) between the two groups. The median follow-up time for the entire cohort was 19.6 months (range 0.2-40.6 months). The 3-year overall survival rate was 62.9% in the CSPH group and 84.3% in the non-CSPH group (p = 0.1090), and results were similar after PSM (p = 0.5734). Conclusions LLR is safe and feasible for HCC with PH. The introduction of minimally invasive surgery, represented by LLR, can appropriately expand the indications for hepatectomy.
机译：背景：对于可切除肝细胞癌（HCC）患者而言，临床意义上的门脉高压（CSPH）仍然是肝切除术的相对禁忌证。本研究的目的是探索腹腔镜方法是否可以将肝切除术的适应症扩展到PH患者。方法2016年2月至2019年9月由一个医疗团队进行腹腔镜肝切除术（LLR）的患者被纳入本研究。我们分析了在倾向性评分匹配（PSM）前后有无CSPH组的手术和肿瘤结果。结果156例患者根据CSPH的存在（CSPH，n=26）或不存在（非CSPH，n=130）分为两组。CSPH组肝功能不全的临床症状较多（p<0.05）。PSM后（n=48名患者），CSPH组术后住院时间较长（p=0.054）；然而，两组在手术时间（p=0.329）、失血量（p=0.392）、输血率（p=0.701）、中转开腹手术率（p=0.666）、手术切缘（p=0.306）、手术死亡率（n=0）或综合并发症指数（p=0.844）方面没有差异。整个队列的中位随访时间为19.6个月（范围为0.2-40.6个月）。CSPH组和非CSPH组的3年总生存率分别为62.9%和84.3%（p=0.1090），PSM后的结果相似（p=0.5734）。结论以LLR为代表的微创手术可以适当扩大肝切除的适应证。

著录项

  • 来源
    《Surgical Endoscopy》 |2021年第7期|共12页
  • 作者

    Zheng Junhao; Feng Xu; Liang Yuelong; Cai Jingwei; Shi Zhaoqi; Kirih Mubarak Ali; Tao Liye; Liang Xiao;

  • 作者单位

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Dept Gen Surg 3 East Qingchun Rd Hangzhou 310016;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Dept Gen Surg 3 East Qingchun Rd Hangzhou 310016;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Dept Gen Surg 3 East Qingchun Rd Hangzhou 310016;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Dept Gen Surg 3 East Qingchun Rd Hangzhou 310016;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Dept Gen Surg 3 East Qingchun Rd Hangzhou 310016;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Dept Gen Surg 3 East Qingchun Rd Hangzhou 310016;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Dept Gen Surg 3 East Qingchun Rd Hangzhou 310016;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Dept Gen Surg 3 East Qingchun Rd Hangzhou 310016;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 诊断学;
  • 关键词

    Laparoscopic liver resection; Portal hypertension; Hepatocellular carcinoma; Survival;

    机译：腹腔镜肝切除术;门脉高压症;肝细胞癌;生存;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号